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Project:  Both  septic  shock  and sodium  selenite  (Na2SeO3) lead  to  multiple  organ  failure  through  oxidation.
Na2SeO3 has  direct  oxidant  effects above  the  nutritional  level  and  indirect  anti-oxidant  properties.
In  a  lipopolysaccharide  (LPS)  rat  model  we  assessed  margin  of safety,  toxicity  and  beneﬁcial  effect  of
pentahydrate  Na2SeO3 (5H2O·Na2SeO3) at oxidant  doses.
Procedure:  In a three-step  study  on  204 rats  we:  (i)  observed  toxic  effects  of  Na2SeO3 injected  intraperito-
neously  (IP) and  determined  its  Minimum  Dose  Without  Toxic  effect  (MDWT)  0.25–0.35  mg/kg  selenium
(Se)  content;  (ii) injected  IP  LPS  at 70% lethal  dose  (LD) followed,  or not, one  hour  later by  IP Na2SeO3 at
MDWT  and  (iii)  by  doses  >  MDWT.  At  48  h, in survivors,  we  measured  plasma  creatinine,  lactate,  aspartate
and  alanine  aminotransferase  (AST, ALT),  nitric  oxide  (NO)  and Se  concentrations.
Results: (i)  Na2SeO3 alone  did  not  increase  NO and  lactate.  Encephalopathy  appeared  at  1  mg  Se/kg.  Cre-
atinine  increased  at 1–1.75  mg  Se/kg,  AST,  ALT  at 3–4.5  mg  Se/kg,  and  the  minimum  LD was 3  mg Se/kg.
(ii)  Mortality  after LPS  was 37/50  (74%,  [62–86%])  vs.  20/30  (67%, [50–84%])  when  followed  by  Na2SeO3 at
MDWT  (p =  0.483)  with  a  decreased  in  NO  (−31%,  p =  0.038)  a trend  for lactate  decrease  (−19%,  p =  0.068)
and  an  increased  Se  in  plasma  of  survivals.  (iii)  All  rats  died  at doses  ≥0.6  mg/kg  (p  < 0.001).
Conclusion: Mechanisms  of LPS  and  Na2SeO3 toxicity  differ  (i.e.  NO,  lactate).  In septic  shock  5H2O·Na2SeO3
toxicity  increased,  margin  of  safety  decrease,  but  IP  administration  of dose  considered  as  oxidant  of
5H2O·Na2SeO3 showed  beneﬁcial  effects.
© 2014  Published  by  Elsevier  GmbH.ntroduction
Septic shock, an uncontrolled systemic host response to inva-
ive infection leading to multiple organ failure, is a major issue due
o its frequency, cost and mortality rate [1]. Its physiopathology
s better understood with increasing data supporting the key role
f oxidant free radicals, especially on endothelium damage [2–5].
here is a growing interest in seleno-compounds in sepsis and more
∗ Corresponding author at: Centre Hospitalier de Meaux, Hôpital Saint Faron, 6-8
ue Saint Fiacre, BP 218, Réanimation Polyvalente, 77104 Meaux,
rance.  Tel.: +33 1 64 35 37 78; fax: +33 1 64 35 37 21.
E-mail addresses: xforceville@invivo.edu,
-forceville@ch-meaux.fr (X. Forceville).
ttp://dx.doi.org/10.1016/j.jtemb.2014.03.010
946-672X/© 2014 Published by Elsevier GmbH.speciﬁcally in sodium selenite (Na2SeO3), however, if many stud-
ies have been performed on Na2SeO3 administration in septic shock
patients [6], to our knowledge, no animal study has been done on
its toxicity in septic animals, and few on mechanism of action [7]. In
addition, Na2SeO3 is known to be a highly toxic compound leading
to multiple organ failure and death [7–9]. Among the compounds
containing selenium (Se), Na2SeO3 is one of the most toxic one
due to its oxidant properties [9–11]. Oxidant properties of seleno-
compounds are related to peripheral electronic structure shared
between oxygen and Se (chalcogen family, or oxygen atom group)
[8,12]. In Na2SeO3, the Se atom is under the Se4+ oxidation degree,
which makes this molecule highly reactive especially on disulfur
bridges [10,13–15]. In septic shock Na2SeO3 may  act as an oxidant
drug reducing the activity of overactivated polymorphonuclears
through its cytotoxic properties and thus reducing the generalized
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verwhelming inﬂammation of septic shock [7,8,16–19]. In vitro, at
oncentrations higher than 2–5 mol  Se/L as Na2SeO3, it reduces
he production of NO in activated cells by an inhibition of NFKB
o DNA binding through oxidative mechanism [20]. It also induces
ytotoxic effect especially in non-adherent cells and in activated
ells [10,13,21]. This effect could be mediated by a toxicity of selen-
te on mitochondria on activated cells such as observed in cancer
ells [13,15,21]. Results of a post-peritonitis sheep study are in favor
f such an oxidant drug action in sepsis [22,23].
Clinical trials, including randomized multicenter study, admin-
strating Na2SeO3 in septic shock patients have shown con-
radictory results, some of them showing a tendency for a
ecrease in mortality, especially those using a bolus administra-
ion [6,16,24–30]. The purpose of most of these studies was  to
eliver Se through selenite (Na2SeO3) administration, considering
his administration as a mere Se supplementation. Indeed, most
uthors currently believe that Na2SeO3, even in bolus injection at
oses largely above nutritional requirement, acts only as a source
f Se required for selenoenzymes synthesis [6,25,27,28,30]. Sele-
oenzymes are one of the major antioxidant enzyme families in
ammals [31–34] and there is a huge oxidative stress in sep-
ic shock by different mechanisms including the respiratory burst
2–5,35–38]. However, despite constant low plasma Se decrease,
 tissue Se deﬁciency has not been shown in sepsis in any exper-
mental study. In plasma, Se is present in selenoprotein-P (Sel-P)
or about 60% and in plasma glutathione peroxidase (GPx-3) for
bout 30%. Plasma Se represents 0.5–1% of the 20–40 mg  Se of the
ody [8,32]. One of the possible anti-oxidant actions for endothe-
ium protection might be an induction of Sel-P. This mechanism
as been proposed in a large phase II study [25]. However Sel-
 has been shown to be a protein of the negative acute phase
esponse, which makes its induction by Se in septic shock at the
arly phase debatable [39]. Moreover the ﬁrst results of the post-
eritonitis sheep study did not ﬁt with such an action, without
eﬁnitive demonstration in the current absence of available Sel-
 dosage in sheep [22,23,40]. Many questions on the toxicity limit
nd mechanism of action, of Na2SeO3 are still open [7,16,25–29].
n one-hand doses above the UL and especially in bolus seems
ore efﬁcient in clinical studies. On the other hand, it is also still
ommonly thought that, in an oxidative state such as septic shock,
a2SeO3 may  have toxic side effects at doses above the Upper
ntake Level (UL) (400 g), with even more effects above the No
dverse Effect Level (NOAEL) (800 g) [16,27,28,41–44]. Until now,
e had no precise indication about toxicity limits of Na2SeO3 in
eptic condition despite numerous clinical studies performed with-
ut preclinical data [7,16,25–29]. These preclinical toxicology data
re needed to determine the safety margin of Na2SeO3 injection
n sepsis patients [7]. This study was conducted to test in a sep-
ic shock animal model the double hypothesis that: (i) high dose
f pentahydrate Na2SeO3 (5H2O·Na2SeO3) has an increased toxic-
ty in septic condition, and to have indication about safety margins
ii) and Na2SeO3 may  also have a beneﬁcial pharmacological effect
t doses currently considered to be toxic due to its oxidant effect
8,17,18].
aterials and methods
In  the present study, we used a common model of acute
nﬂammation related to sepsis by intraperitoneal (IP) injections of
ipopolysaccharide (LPS) in rats [45–47]. IP injection of Na2SeO3
n rat is also a common model to test its toxicity [9,48,49]. We
onducted a three-step study to test the double hypothesis. In the
rst step, we evaluated the toxic effects of Na2SeO3 and of LPS. We
etermined the 70% lethal dose (LD) for LPS and the Minimum Dose
ithout Toxic effect for Na2SeO3 (MDWT). In the second step, weMedicine and Biology 28 (2014) 303–310
induced  sepsis by injecting the previously determined 70% LD for
LPS followed one hour later by the Na2SeO3 at the MDWT to deter-
mine if Na2SeO3 could have therapeutic effects at nearly toxic dose.
In a third step we  induced similarly sepsis and observed mortality
after Na2SeO3 IP injection at doses higher than the MDWT.
Animals
Animal housing and experimental procedures were approved
by the Ethics Committee on Animal Research of the French Armed
Forces Biological Research Institute (IRBA), in accordance with the
French ethical guidelines under the number 50/2001. All exper-
iments were conducted on 9-week-old male IOPS Han Ico Wistar
rats (Charles River, L’Arbresle, France). Animal weight was  between
240 and 280 g at the experimentation time. They were housed
in individual conﬁnements in thermoformed polystyrene cages in
accordance with standards accredited by the French Ministry of
Agriculture and Environment at a temperature of 21 ± 1 ◦C, with
55% relative humidity and a 12 h light–dark cycle. They had free
access to food (SAFE, Augy, France) containing 0.190 mg  Se/kg of
food and to water corresponding to an adequate Se intake [50]. To
minimize experimental stressors, rats where acclimatized to the
laboratory environment for one week prior to experiments.
Experimental protocol
This  study was divided into three distinct steps involving 204
rats. They were conducted to evaluate the effects of an IP injection
of 5H2O·Na2SeO3: ﬁrstly in healthy rats allowing to determine the
MDWT,  secondly in rats with an endotoxin shock induced by LPS
administrated IP at doses corresponding to the previously deter-
mined MDWT  doses and thirdly at higher 5H2O·Na2SeO3 doses. In
each experiment the rats received two IP injections at 1-h interval
(see Fig. 1). When administered, the same LPS dose (26 mg/kg) was
used in all experiments. This dose was  previously determined in
our laboratory as the dose inducing between 60 and 70% mortality
(70 LD) during the ﬁrst 48 h following IP injection of LPS (data not
shown) (26 mg/kg of LPS) (Salmonella typhimurium, Sigma–Aldrich,
France). A 70% mortality rate was  chosen in order to observe if
sodium selenite might increase the mortality related to sepsis, or
decrease it at a dose just below the toxic dose. The selenite used was
the pentahydrate sodium selenite (5H2O·Na2SeO3, Fluka, France)
diluted with standard sterilized water, which is the form of selenite
used in clinical study by us and others [25,26].
First step of the study: intraperitoneal Na2SeO3 toxicity in normal
rats
The objective of the ﬁrst set of experiments was to determine in
74 healthy rats the MDWT  of Na2SeO3 administrated IP, as well as
its minimum LD dose (Fig. 1a).
In the 74 rats, we  ﬁrst injected 2.5 mL  saline water through IP.
One hour later, the rats were divided into seven groups (Fig. 1a). The
control rats received a second saline injection (n = 12). The 62 other
rats were divided into six groups each receiving different doses of
Na2SeO3 expressed in Se content from 0.25 to 4.5 mg  Se/kg (Fig. 1a).
For analytical reasons (number of sampled rats among those who
survived 48 h), the six groups of rats were grouped together into
three groups (1, 2, 3) according to the dose received (expressed in
selenium – Se – content). Group 1 received Na2SeO3 dose corre-
sponding to 0.25 or 0.35 mg/kg Se (Na2SeO3 dose 1, n = 20). Group
2 received Na2SeO3 dose corresponding to 1 or 1.75 mg/kg Se
(Na2SeO3 dose 2, n = 20) and Group 3 Na2SeO3 dose corresponding
to 3 or 4.5 mg/kg Se (Na2SeO3 dose 3, n = 22) content. Na2SeO3 was
diluted in saline water (1 mL  per 100 g of body weight), and injected
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Fig. 1. IP: intraperitoneal, Na2SeO3: pentahydrate sodium selenite, LPS: lipopolysaccharide, LD: lethal dose. For both steps, mortality and biological parameters were assessed
48  h after the second injection, MDWT:  Minimum Dose Without Toxic effect in healthy animals. Dose 1 corresponded to an administration of pentahydrate sodium selenite
(Na2SeO3·5H2O) expressed in selenium (Se) content of 0.25 or 0.35 mg Se/kg body weight; dose 2 of 1 or 1.75 mg/kg; dose 3 of 3 or 4.5 mg/kg. Dose 1 was determined as the
MDWT.  Doses in (C) corresponded to an administration of pentahydrate sodium selenite (Na2SeO3·5H2O) expressed in Se content.
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Fig. 2. Data are means ± standard deviations. In each group, the number of sam-
pled surviving rats is indicated in bracket. Na2SeO3 (sodium selenite) injected IP06 X. Forceville et al. / Journal of Trace Eleme
hrough IP. Clinical and biological evaluations and mortality were
ssessed 48 h after the second IP injections.
econd step of the study: intraperitoneal Na2SeO3 effects in LPS
reated rats
Using  the results of the ﬁrst experiment, in the second one we
nduced septic shock by injection of 70% LD dose of LPS and tested
hether the MDWT  of Na2SeO3 could have a therapeutic effect
Fig. 1b).
In  this step 80 rats were tested. They all received IP LPS injection.
ne hour later, Group A (n = 50) received IP saline vehicle (1 mL  per
00 g of body weight) (LPS control group). Group B (n = 30) received
P Na2SeO3 injection (0.25–0.35 mg/kg). As in the ﬁrst experiment,
linical and biological evaluations and mortality were assessed 48 h
fter the second IP injections.
hird  step of the study: intraperitoneal Na2SeO3 effects in LPS
reated rats at dose higher than the MDWT
Similarly to the second step, septic shock was induced in rats.
e tested whether doses higher than the MDWT  had toxic effects.
In this step 50 rats were tested. They all received LPS injection.
ne hour later, rats received IP Na2SeO3 injection at doses 0.6, 1,
.75, 3 and 4 mg/kg (n = 10 each dose) (Fig. 1c).
iological endpoints
At  the end of each 48 h follow-up period, blood samples were
rawn in part of the surviving rats of each group, in order to
llow biochemical assays. To allow trace element analysis, oligo-
ree needles, syringes and tubes were used. Blood was collected
nder halothane anesthesia by vena cava puncture with EDTA and
eparin-Lithium (HL) as anticoagulant and then the rats were killed
y sectioning heart vessels. Especially in hypovolemic rats both
DTA and HL, blood sampling could not be always done. After cen-
rifugation at 2000 g for 15 min., plasma samples were stored at
80 ◦C until analysis. HL plasma levels of creatinine, lactic acid,
spartate aminotransferase (AST) and alanine aminotransferase
ALT) were measured with an automatic analytical instrument
Hitachi 912, Roche Diagnostics, Meylan, France). The values for
ach sample were evaluated using normal and pathological stan-
ards, Précinorm® U and Précipath® U (Roche Diagnostics, Meylan,
rance). Nitric oxide (NO) plasma concentration was measured in
DTA plasma samples using a speciﬁc enzyme-linked immunosor-
ent assay (ELISA) technique according to the manufacturer’s
nstructions (R&D Systems Europe, Lille, France). The minimum
etectable concentration for NO was less than 3.12 mol/L. Se
oncentration was measured in HL plasma using capillary gas
hromatography–mass spectrometry (TRIO 1000, ThermoQuest,
es Ulis, France) in single ion recording according to Ducros and
avier methodology [51]. As this study was focused on mortality
nd toxicity no measurement of plasma glutathione peroxidase and
elenoprotein-P was performed.
tatistical analysis
Reported  values are expressed as means ± standard deviation
or quantitative variables or numbers and percentages for qual-
tative variables. Statistical analysis was performed with SAS
tatistical software V9.1 (SAS Institute, Cary, NC). Our statistical
lan included two distinct analyses. In the ﬁrst step of the study,
iological parameters were compared between the four groups
sing a one-way analysis of variance or the Kruskal–Wallis Test,
hen needed. In case of a statistically signiﬁcant difference, pair-
ise comparisons were performed using the Student’s t test with
onferroni correction. In the second step of the study, biological
arameters were compared between the two LPS groups – within Groups 1, 2 and 3 correspond to 0.25 or 0.35 mg/kg, 1 or 1.75 mg/kg, and 3 or
4.5 mg/kg Se content respectively; p < 0.001 (ANOVA) between the 4 groups. *p < 0.05
vs Control (Bonferroni correction).
and without selenite administration – using the Student’s t test or
the Wilcoxon rank sum test when needed. Survival rates at 48 h
were compared using the chi-square test. In each case, a p value
<0.05 was  considered statistically signiﬁcant.
Results
First step of the study
For  doses of Se greater than 1 mg/kg, rats had typical neu-
rological acute toxicity symptoms such as transient wandering
difﬁculties, especially with hind legs. Some of them presented also
a clinical aspect of encephalopathy, lying on their backs and even
eating on their backs.
Biological  variables measured in the ﬁrst experiment are shown
in Table 1 and Fig. 2. Mean plasma creatinine concentrations
increased signiﬁcantly in animals receiving Na2SeO3 doses 2 and 3
as compared to the control group (+104% with Na2SeO3 dose 2 and
+126% with Na2SeO3 dose 3, p < 0.05) and also as compared to the
Na2SeO3 dose 1 group (+96% with Na2SeO3 dose 2 and +118% with
Na2SeO3 dose 3, p < 0.05). Mean plasma AST and ALT concentrations
were signiﬁcantly higher in animals receiving Na2SeO3 dose 3 as
compared to all other groups. No signiﬁcant differences between
groups were observed for lactic acid and NO plasma concentra-
tions. Compared to the control group, plasma Se concentration was
signiﬁcantly increased only with Na2SeO3 dose 3 (Fig. 2).
No  rats died within 48 h neither in the control group nor in the
two groups of animals receiving the four smallest Se doses (0.25,
0.35, 1 and 1.75 mg/kg). In the Na2SeO3 dose 3 group, 4/22 animals
died within 48 h (18% mortality, [95% conﬁdence interval: 2–34%]).
Second step of the study
Rats  receiving IP 26 mg/kg dose LPS alone in 3 mL water (Fig. 1B)
rapidly showed signs of severe sepsis in a few hours. They rolled
up into a ball. Their fur was  dull and stood on end. They were
prostrated, asthenic and had diarrhea. LPS non-surviving rats died
mostly in less than 24 h in an asthenic syndrome and LPS alone sur-
viving rats remained very asthenic at 48 h. Although not quantiﬁed
and a subjective observation, Na2SeO3 treated rats seemed to be
healthier showing less prostration and asthenia.
Plasma Se concentrations increased at 48 h in animals receiv-
ing Na2SeO3 dose 1 (Fig. 3) compared to those receiving LPS alone.
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Table  1
Organ dysfunction biological variables in the control and Na2SeO3 treated rats.
Variable Control (n = 12) Na2SeO3 Group 1 (n = 14) Na2SeO3 Group 2 (n = 4) Na2SeO3 Group 3 (n = 5) p
Creatinine (mol/L) 27 ± 12d 28 ± 13d 55 ± 6 61 ± 22 0.001
AST  (UI/L) 60 ± 7 88 ± 27 89 ± 18 531 ± 321e <0.001
ALT  (UI/L) 35 ± 7 41 ± 9 30 ± 11 80 ± 39e 0.03
Lactic  acid (mmol/L) 3.39 ± 0.18a 4.45 ± 1.91a 3.05 ± 0.30 4.28 ± 1.91b NS
NO  (mol/L) 21 ± 7c 27 ± 10a 29 ± 12 24 ± 10b NS
Data are means ± standard deviations.
Na2SeO3 (sodium selenite); doses 1, 2 and 3 correspond to 0.25–0.35 mg/kg, 1–1.75 mg/kg, and 3–4.5 mg/kg selenium content; AST, aspartate aminotransferase; ALT, alanine
aminotransferase ALT; NO, nitric oxide.
a n = 2.
b n = 4.
P
p
i
d
S
v
r
r
c
P
c
a
t
v
n
A
6
5
T
0
a
t
F
b
r
N
0
lowed by 5H2O·Na2SeO3 at MDWT  (20/30), p < 0.001. Samples could
be obtained in one animal close to its death in the 0.6 mg/kg group.
Low blood volume could be obtained. Therefore, only the followingc n = 6.
d vs Na2SeO3 doses 2 and 3 (Bonferroni correction).
e vs Control and Na2SeO3 doses 1 and 2 (Bonferroni correction).
lasma Se concentration decreased in LPS treated animals as com-
ared to the control animals of the ﬁrst step (4.62 ± 0.24 mol/L
n controls and 3.50 ± 0.50 mol/L with LPS, p = 0.001). Na2SeO3
ose 1 supplementation to LPS treated animals restored plasma
e concentrations to normal values (4.27 ± 0.65 mol/L, p = 0.157
s. controls of the ﬁrst step).
Plasma  NO concentration signiﬁcantly decreased in animals
eceiving Na2SeO3 (Fig. 4A, −31%, p = 0.038) compared to those
eceiving LPS alone. Although non signiﬁcant, plasma lactic acid
oncentration also tended to decrease (Fig. 4B, −19%, p = 0.068).
lasma lactic acid concentrations increased in LPS treated animals
ompared to control animals of the ﬁrst step (3.39 ± 0.18 in controls
nd 4.81 ± 0.80 with LPS, p = 0.045). Na2SeO3 dose 1 supplemen-
ation in LPS treated animals restored values similar to normal
alues (3.88 ± 0.72, p = 0.314 vs controls of the ﬁrst step). No sig-
iﬁcant differences between groups were observed for creatinine,
ST and ALT plasma concentrations (data not shown).
Mortality at 48 h was 37/50 (74%, [95% conﬁdence interval:
2–86%]) with LPS alone and 20/30 (67%, [95% conﬁdence interval:
0–84%]) in the LPS animals receiving Na2SeO3 (p = 0.483).
hird step of the studyAll  animals (50/50) receiving doses equal or higher than
.6 mg/kg 5H2O·Na2SeO3 died before 48 h follow-up period, mainly
fter a 5 h clinically free period interval from acute respiratory dis-
ress associated to tinged with blood sputum, suggesting an acute
ig. 3. Data are means ± standard deviations (SD). In bracket are indicated the num-
er of sampled rats among the surviving rats at 48 h. Mean ± SD values in control
ats  are indicated as doted lower and upper lines (n = 7). LPS (lipopolysaccharide);
a2SeO3 (sodium selenite); Na2SeO3 administrated doses in Group B correspond to
.25–0.35 mg  Se/kg (dose 1).pulmonary edema. This mortality rate is signiﬁcantly increased
compared to those of rats receiving LPS only (37/50), or LPS fol-Fig. 4. Data are means ± standard deviations (SD). In bracket are indicated the num-
ber of sampled rats among the surviving rats at 48 h. LPS (lipopolysaccharide);
Na2SeO3 (sodium selenite); LPS (lipopolysaccharide); Na2SeO3 (sodium selenite);
Na2SeO3 administrated doses in Group B correspond to 0.25–0.35 mg Se/kg (dose 1).
Values for nitric oxide (NO) concentration were 283 mol/L for Na2SeO3 dose corre-
sponding  to 0.25 mg Se/kg and 256 mol/L for 0.35 mg Se/kg respectively. Mean ± SD
values for (NO) (n = 6) and for lactate acid (n = 2) in control rats are indicated as lower
and upper doted lines.
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arameters were obtained: creatinine 77 mol/L, AST 131 UI/L,
LAT 51 UI/L, plasma Se concentration 13.9 mol/L.
iscussion
This  is the ﬁrst study that evaluates in the same animal model
he IP toxicity of pentahydrate sodium selenite (5H2O·Na2SeO3), a
mall Se-containing compound, and the IP toxicity of lipopolysac-
haride (LPS) at 70% LD and to determine IP 5H2O·Na2SeO3 toxicity
n septic shock animals in a post-LPS model. Even though high
oses of Na2SeO3 and LPS are both known to lead to multiple
rgan failure and death caused by pathophysiological mechanisms
nvolving hyperoxidation, their mechanisms differ signiﬁcantly.
his is shown by the absence of signiﬁcant increase of plasma NO
nd lactate concentration in selenite acute intoxication contrary to
heir marked increase in LPS toxicity.
The minimum LD dose for Na2SeO3 was lower in septic
ompared to healthy rats (lower than 0.6 mg/kg vs 3 mg/kg Se
s 5H2O·Na2SeO3). This is in favor of an increased toxicity of
H2O·Na2SeO3 in septic condition. However, IP administration of
a2SeO3 at Minimum Dose Without Toxic effect (MDWT) dose
0.25–0.35 mg/kg Se) one hour after administration of 70% LD of
PS may  be beneﬁcial as shown by the decrease of NO concentration
ompared to animal receiving LPS only.
ats: a resistant to oxidation model, possible link with plasma
elenoproteins
In  accordance with previous ﬁnding, plasma Se concentration
n healthy rats was ﬁve times higher than in man  [52,53]. This
ay allow rats to support a higher hyperoxidation than man  and
ay  partially explain rats’ higher resistance to infection compared
o men  [54,55]. Similar to the decrease in plasma Se observed in
CU patients, we observed a decrease in plasma Se concentration in
urviving LPS rats [22,50,52,56,57].
argin  of safety of Na2SeO3
Among seleno-compounds, Na2SeO3 is a relatively high oxidant
elenocompound [10,17] and therefore listed as highly toxic [11].
ne can notice that Na2SeO3 is as toxic as arsenic salt in rat in IP
njection [48]. In rat, the 50% LD of Se, which is physico-chemically
lose to oxygen [10], varied: from 2.5 mg  Se/kg if administrated
s Na2SeO3 to 6.7 g Se/kg if administrated as elemental Se [43,58].
ur results for a minimum LD of 3 mg  Se/kg for Na2SeO3 in healthy
at are in accordance with previous reports on mortality, as are
ur results on renal and hepatic toxicity already described in
ealthy mammals including men  in acute intoxication or poisoning
9,48,49,59,60]. In our study, the kinetic of plasma Na2O3Se after IP
njection following IP LPS administration may  be more likely sim-
lar to a continuous administration resulting in a plateau than an
ntravenous (IV) bolus injection resulting in a peak of concentration
22]. IP is therefore likely to be less toxic than IV bolus administra-
ion [9,10,49,59]. We  nevertheless observed a marked increased
oxicity of Na2SeO3 in LPS compared to healthy rat, which is in
ccordance with the increased cytotoxicity of Na2SeO3 in activated
ells compared to non-activated cells [13,21].
In humans, many authors believe that in such an oxidative
tate as septic shock, Na2SeO3 has toxic side effects at doses
bove the nutritional limits UL (400 g/day) or the NOAEL (800 g)
16,27,28,41–44]. On the contrary, other authors believe that
igher doses than NOAEL are required for Se supplementation
6,25,30,61]. Very few support Na2SeO3 acting as cytotoxic drug,
specially when administrated in bolus, such as has been proposed
n cancer [7,10,19,21,61,62]. In the last two cases, with Na2SeO3
dministration at high doses, determination of the security marginMedicine and Biology 28 (2014) 303–310
is  required. In septic shock ICU patients mortality tends to decrease
in clinical studies using Na2SeO3 in bolus at doses largely above UL
[6,16,25], but not in those were it is administrated continuously
[16,25,26,63]. In a post-peritonitis sheep study, bolus was  needed
for efﬁciency, supporting an oxidant drug action [22,23,40]. For
the use of Na2SeO3 as a chemotherapeutic agent, a phase I study
has been conducted in stabilized drug resistant cancer patients
using bolus administration of Na2SeO3. This study was presented
recently in the 10th International Symposium on Selenium [64].
According to the authors the toxicity limit of IV bolus injection in
stable patients was  10.2 mg  Se/m2 (about 0.25 mg/kg) [64] which
is less than the one estimated in ingestion (about 3 mg/kg) [9]. Our
study supports that the margin of safety of Na2SeO3 be also further
restricted in septic shock compared to stable condition.
Oxidant beneﬁcial effect of Na2SeO3 acting as drug in sepsis?
As an illustration of the close link between a drug and a poi-
son, and the need to determine the safety margin, the IP Na2SeO3
injection at 0.25–0.35 mg  Se/kg seemed beneﬁcial, when its admin-
istration at 0.6 mg  Se/kg was  lethal.
In accordance with our hypothesis, we  observed, a NO reduction
at this IP dose of Na2SeO3 administrated after the LPS injection
compared to LPS rat. This is in accordance with in vitro studies
where large concentrations of Na2SeO3 result in reversible inhi-
bition of NO synthesis [20,65,66], or a cytotoxic effect observed in
activated cells such as cancer cells [67,68]. This cytotoxic action will
require to reach a blood concentration known to be toxic for cells
in vitro, and especially on non-adherent cells (>2–5 mol  Se/L as
Na2SeO3) [8,10,17,18,21]. It may  be beneﬁcial in sepsis by reducing
the activity of over-activated phagocytic cells [7,8,17,18] and may
explain the results obtained in clinical studies when Na2SeO3 is
injected in bolus [7]. The trend of reduced lactate concentrations is
also in accordance with results of the post-peritonitis sheep study,
which support an oxidant cytotoxic drug action of Na2SeO3, that
requires to reach a high level of plasma Na2SeO3 concentration
(>2–5 mol  Se/L). This concentration was only obtained in bolus
in this study where Na2SeO3 was administrated after the onset of
peritonitis [22]. Contrary to stable condition the cells and especially
the circulating phagocytic cells are over-activated in septic shock.
In this condition, the administration of Na2SeO3 is more likely to act
through its cytotoxicity [10,13,15,21]. An induction of selenopro-
tein synthesis by Na2SeO3 is unlikely in over-activated condition
contrary to non-activated one [21] and has never been studied at
the early hours after injection in a post-sepsis model. In addition,
the main plasma selenoprotein (selenoprotein-P) belongs to the
negative acute phase response of septic shock [39].
Limitations
This rat study did not allow to conclude if the observed reduc-
tion of NO is related to an oxidative effect of high dose Na2SeO3 or
to an anti-oxidant indirect effect through Se inducing selenoen-
zymes, such as GPx or selenoprotein-P, synthesis [25,40,66,69].
Further studies are required to determine this, with selenoprotein-
P and plasma GPx dosages during the ﬁrst hours following Na2SeO3
injection [23,40]. This study has several additional limitations for
transposition to ICU patients. Firstly, regarding the animal model,
as in all studies with rats, we recruited young, healthy rats weight-
ing 300 g, for an average weight of 800 g for an adult. In addition,
only male rats were selected. Secondly, concerning the supportive
therapies, the animals did not receive sedation, mechanical venti-
lation, vasopressor therapy, active ﬂuid resuscitation or antibiotics
that may  be required in cases of bacterial translocation. Thirdly
there was no follow-up of hemodynamic nor pulmonary function.
Fourthly, since the reference range for plasma Se is 5 times higher
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han in man, and if selenoprotein-P has a major antioxidant func-
ion, rats may  be more tolerant to very high intakes of oxidant doses
f Na2SeO3 than humans [54,55,70]. Fourthly, sampling was  limited
o part of the surviving animals limiting the power of statistical
nalysis especially for lactate concentration. Fifthly, this model was
ssentially performed to evaluate the security margin of continu-
us administration, but not for the more dangerous intravenous
olus administration allowing higher selenite blood concentration
han IP administration. On the other hand, regarding the beneﬁcial
ffect of oxidant Na2SeO3 dose, which was not the main objective
f this study, other parameters than plasma Se, lactate and NO con-
entration should be studied further to precisely understand the
echanism of action.
onclusion
Even  though high doses of sodium selenite (Na2SeO3) and
PS are both known to lead to multiple organ failure and death
aused by pathophysiological mechanisms involving hyperoxida-
ion, their mechanisms seem to differ signiﬁcantly as shown by
heir markedly different effects on NO and lactate concentrations
bserved in this study. In our study the toxicity of IP administra-
ion of sodium selenite increased in septic shock rats compared
o healthy rats, which are especially resistant animals to aggres-
ion. Toxicity of sodium selenite may  be higher in septic shock
CU patients than in rats. Moreover, our model is more similar to a
ontinuous administration than to an intravenous bolus adminis-
ration, which is believed to cause higher toxicity. In addition, this
tudy did not explore long-term toxicity.
Further studies are required to be more precise about (i) the
echanism of action of Na2SeO3, especially just after a bolus injec-
ion. Na2SeO3 could act as an oxidant cytotoxic drug (especially on
yper-activated circulating phagocytic cells) or as Se supplier for
ntioxidant selenoenzymes such as GPx or selenoprotein-P syn-
hesis; (ii) rodent and non-rodent septic shock animal studies are
lso required, to determine more precisely Na2SeO3 toxicity limit
n sepsis. The publication of the results of the previously cited
hase I study on Na2SeO3 bolus administration as second line
hemotherapy in resistant cancer may  be of great interest for safety
argin determination, taking into account the increased toxicity of
a2SeO3 in sepsis shown in our study.
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